
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep is a promising biotechnology company with a diversified product portfolio that focuses on developing LAG-3 related immunotherapies for cancer and autoimmune diseases. The company's efti drug has shown promising results in Phase 2 trials for breast cancer and is currently being evaluated in a Phase 3 trial for NSCLC. With experienced leadership and partnerships with other pharmaceutical companies for global development, Immutep has strong potential for success in the future.
Bears say
Immutep is currently a high-risk investment due to uncertainties surrounding their lead product's success in Phase 3 trials and its potential impact on the projected market. There is also limited information available on the progress of their other products, which may hinder their potential for revenue diversification. Furthermore, the company has a high cash burn rate and a history of losses, which may require additional financing in the near future.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares